The case for & against
Bull & Bear analysis
Bearish
Athenex, Inc. (ATNX) was formerly engaged in the development and commercialization of innovative therapeutics for the treatment of cancer. It focused on creating proprietary oral and intravenous formulations of chemotherapeutics to enhance drug delivery and reduce toxicity. Unfortunately, due to a string of operational challenges and failures to achieve market goals, Athenex has faced significant financial decline, leading to its recent delisting from the stock exchange. The company is now effectively inactive in the capital markets, having experienced a nearly 100% decline since its inception.
Bull says
- ↑Former pipeline includes oral and IV cancer therapies
- ↑R&D team has history developing novel drug formulations
- ↑Shares near zero may attract contrarian or turnaround buyers
- ↑Potential acquisition or external capital injection remains a catalyst
- ↑Broader biotech rally could spur speculative interest in distressed names
- ↑Absence of visible financial metrics increases uncertainty and limits conviction
Bear says
- ↓Delisted from exchange, destroying market access and investor interest
- ↓Shares have plunged nearly 100%; last closing price $0.02
- ↓Zero daily trading volume as of August 2026 indicates illiquidity
- ↓No revenue generation and an inactive pipeline post-failed trials
- ↓Analyst forecast of $0.19 by end-2026 implies minimal upside
- ↓Repeated trial failures underscore deep operational and viability issues